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Abstract
Background: The amount of research utilizing health information has increased dramatically over the last ten years. Many
institutions have extensive biobank holdings collected over a number of years for clinical and teaching purposes, but are
uncertain as to the proper circumstances in which to permit research uses of these samples. Research Ethics Boards (REBs) in
Canada and elsewhere in the world are grappling with these issues, but lack clear guidance regarding their role in the creation
of and access to registries and biobanks.
Methods: Chairs of 34 REBS and/or REB Administrators affiliated with Faculties of Medicine in Canadian universities were
interviewed. Interviews consisted of structured questions dealing with diabetes-related scenarios, with open-ended responses
and probing for rationales. The two scenarios involved the development of a diabetes registry using clinical encounter data
across several physicians' practices, and the addition of biological samples to the registry to create a biobank.
Results: There was a wide range of responses given for the questions raised in the scenarios, indicating a lack of clarity about
the role of REBs in registries and biobanks. With respect to the creation of a registry, a minority of sites felt that consent was
not required for the information to be entered into the registry. Whether patient consent was required for information to be
entered into the registry and the duration for which the consent would be operative differed across sites. With respect to the
creation of a biobank linked to the registry, a majority of sites viewed biobank information as qualitatively different from other
types of personal health information. All respondents agreed that patient consent was needed for blood samples to be placed
in the biobank but the duration of consent again varied.
Conclusion: Participants were more attuned to issues surrounding biobanks as compared to registries and demonstrated a
higher level of concern regarding biobanks. As registries and biobanks expand, there is a need for critical analysis of suitable
roles for REBs and subsequent guidance on these topics. The authors conclude by recommending REB participation in the
creation of registries and biobanks and the eventual drafting of comprehensive legislation.
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Background
The amount of research utilizing health information has
increased dramatically over the last ten years. Single, time-
limited studies with tightly-defined research questions are
giving way to programs of research that rely upon the sys-
tematic prospective collection of data in registries and
biobanks for subsequent use in multiple projects to
answer as yet unknown research questions. Many institu-
tions have extensive biobank holdings collected over a
number of years for clinical and teaching purposes, but
are uncertain as to the proper circumstances in which to
permit research uses of these samples. Research Ethics
Boards (REBs) in Canada and elsewhere in the world are
grappling with these issues, but have not received clear
guidance regarding their role in the creation of and access
to registries and biobanks. Historically, REBs have played
an active role regarding specific project-by-project
requests exclusively, thus not engaging in some of the
larger issues concerning the creation and research uses of
registries and biobanks. Indeed, some may not even be
aware of the extent of registry and biobank holdings
within their institutions. REBs we interviewed expressed
concern and confusion both as to the handling of specific
projects emanating from registries and biobanks, and to
the broader issues surrounding them.
In this paper we outline variation in the responses of a
wide sampling of REBs across Canada to a series of ques-
tions regarding the creation and use of registry and
biobank information for health research purposes, and we
note the heightened tension surrounding biobanks. We
then discuss the implications of our findings for the devel-
opment of policy and legislation.
Methods
Design & Sample
We approached the Chairs of 34 REBs affiliated with Fac-
ulties of Medicine in Canadian universities and requested
interviews with them and/or with their REB Administra-
tors. They were also invited to include other REB members
in the interview. The interview was to be 90-minutes face-
to-face. Ethics approval was obtained from Research Eth-
ics Boards at the universities of McMaster, Dalhousie, and
Montreal and at St. Joseph Healthcare, Hamilton,
Ontario.
Procedure
Interviews consisted of structured questions dealing with
diabetes-related scenarios, with open-ended responses
and probing for rationales. The two scenarios discussed in
this paper involved the development of a diabetes registry
using clinical encounter data across several physicians'
practices, and the addition of biological samples to the
registry to create a biobank [1]. All interviews but one
were audio-recorded.
Scenarios
The registry scenario involved the construction of a multi-
centre multi-jurisdictional diabetes registry to serve as an
ongoing resource for conducting epidemiologic and proc-
ess-outcome studies. No specific research questions were
identified. Instead, this was intended to provide a general
research platform for future epidemiologic studies. The
plan was to collect data through physician practices. At a
regular patient visit, the physician would complete a
duplicate encounter form. One copy would go in the
patient's file; the second would be supplied to the research
associate at the principal investigator's office, who was
then to remove any direct identifiers and forward the data
to the central registry. This registry was intended to be
updated during routine patient care visits, and was to con-
tinue indefinitely. The research associate would hold the
identification key in order to link newly received informa-
tion with that already received for the particular patient.
[See additional file 1]
In the biobank scenario, blood samples were to be taken
from patients during, but in addition to, routine patient
care. The samples were to be retained indefinitely. The
information garnered from the blood samples would be
linked with the diabetes registry using a common study
ID. The combined biobank and registry were intended to
serve as an ongoing resource for studying biological mark-
ers of diabetes and conducting pedigree studies.
[See additional file 2]
Main Outcome Measures
Major questions asked were as follows:
￿ In terms of the creation of registries, we asked whether or
not patient consent is required for inclusion in a registry,
and the rationale. We also queried the duration of consent
– that is, whether it should last for the duration of the reg-
istry or if periodic renewal would be required – and the
reasoning behind their views on duration.
￿ As to the operation of registries, we inquired into the need
(or lack thereof) for ongoing monitoring of the registry by
the REB, and the types of information that would need to
be reported. We also probed whether the REB would
review the individual research projects utilizing the regis-
try, and the factors that contributed to this decision.
￿ We asked whether the REB viewed biobanks as qualita-
tively different from registries, and the reasons behind
their views. Further, we queried the need (or not) for con-
sent and, if needed, its duration.
￿ We also inquired into any additional reporting require-
ments surrounding biobanks.BMC Medical Ethics 2008, 9:17 http://www.biomedcentral.com/1472-6939/9/17
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Embedded Issues
A number of issues were built into the scenario. These
included the implications of requesting REB review with-
out a specific set of research questions attached to the cre-
ation of the registry/biobank, but rather only a general
research agenda. In the case of the registry, the data were
to be sent offsite to the principal investigator's office for
coding and removal of identifiers. For the biobank, a com-
mon study ID would be used for both the biological sam-
ples and the clinical data in order to facilitate linkage.
Analysis
Interviews were transcribed, checked for accuracy against
the original audio recordings, and forwarded to interview-
ees to review for accuracy and for clarification where the
initial response may have been unclear. Transcript review
moved through several iterations that can be summarized
into two stages. In stage 1, all co-investigators reviewed
the first 11 interviews and, based on these, identified
themes and sub-themes to pursue in the analysis and
response categories. In stage 2, the interviewers and a
graduate student reviewed all transcripts (including those
that had been reviewed in stage 1), coded responses
according to the themes identified, and summarized
respondents' rationales. In some cases, additional themes
emerged or additional nuances were identified for the
original themes. When responses were difficult to catego-
rize, the P.I. independently coded these sections. Answers
and rationales were then discussed as a group to reach
consensus. In a few remaining instances, answers were not
classifiable due to a lack of clarity; this is noted where
applicable in the results section.
To support the interpretations drawn by the researchers,
short examples or typical statements have been included
in the text. Quotations are presented in italics. Minimal
editing has been done to preserve authenticity while
ensuring readability.
Results
Thirty 90-minute face-to-face interviews were conducted
with Chairs and/or Administrators (response rate 88%).
In some cases, one or more other REB members also
attended, to a maximum of seven in attendance. The
median number of attendees was two.
Registry
Of the thirty sites, one refused to entertain the scenario
regarding the creation of the registry, indicating that its
creation was not connected with any specific research
question and therefore falls outside its mandate. Their
concern was a blurring of the concept of creation of
research infrastructure with that of review of research pro-
tocols, and that approving the infrastructure would open
the door to unapproved data uses by the researcher. The
remainder of questions in this section were skipped for
this site. The other twenty-nine sites responded.
In response to the question as to whether patient consent
is required for inclusion of her/his data in the registry,
twenty-three of twenty-nine sites answered affirmatively.
Reasons included the planned collection of identifiable
data; the intention to utilize the data for research in
future; the fact that identifiable data would be going off-
site; and the plan to collect data prospectively, meaning
that there would be ongoing contact with the patients and
therefore seeking consent would not be onerous. Sixteen
of these sites indicated they would not be sympathetic to
an argument by the researcher that seeking individual
consent is impracticable.
Six sites indicated that consent would not be required for
creation of the registry. Three of these did not consider
this to be research; one indicated "this sounds more like
ongoing chart review", and another that "it's an explora-
tory study on a large volume of data." Two of the sites
would not require consent because the data would be
stripped of direct identifiers prior to its entry into the reg-
istry. Two sites not requiring consent would place condi-
tions on the creator of the database – i.e., either an
information letter to patients or notification with opt-out.
Of the twenty-three sites that would require consent, there
was a high degree of variation as to limits on its duration.
Twelve agreed, but for differing reasons, that the patient's
consent would run for the duration of the registry in the
absence of significant change. Of these, two sites saw no
reason for periodic renewal of consent; five indicated pro-
viding an option to withdraw would obviate the need to
require consent renewal; and three sites were motivated
by the fact that they would require consent for specific
research studies utilizing the registry. Another reason
given was that the registry would lose scientific validity
over time if periodic consent were required. Five sites
would require periodic renewal, with the periods ranging
from every subsequent patient visit to once every five
years. This was viewed as feasible given that the patients
are to be followed in the course of routine clinical care.
Four sites were undecided, indicating that the duration of
consent would be decided on a case-by-case basis. One
site's answer was indecipherable and we were unable to
get clarification on follow-up.
Twenty-four of twenty-nine sites would require periodic
reporting to the REB by the registry custodians. Along with
standard information for progress reports, the content of
such reports would include registry-specific information
such as how the registry is being managed, who has access,
the evolution of the population (i.e., enrolments and
withdrawals), and the source(s) of funding of the registry.BMC Medical Ethics 2008, 9:17 http://www.biomedcentral.com/1472-6939/9/17
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In the case of the five remaining sites, one was undecided,
in one case the answer was unclear, in one case the ques-
tion was skipped, one indicated it would only require
reporting in case of amendments to the registry, and the
final site would not require periodic reporting due to a
lack of resources for follow-up.
The twenty-nine sites were also asked whether specific
research projects utilizing the registry would require REB
review. Twenty answered in the affirmative, although
three of these twenty indicated that such review would
likely be expedited (i.e., not reviewed by the full REB).
One site said 'no', while six provided responses condi-
tional on the circumstances; for three of the six, review
would not be required if the data was de-identified; for
two, it would depend on whether there were substantial
changes to the protocol consented to upon establishment
of the registry; and for one, review would only be required
if dramatically different uses were to be made of the data
(e.g., linkage to blood samples). Two sites were unde-
cided.
Registry Combined with Biological Samples
One REB viewed the creation of a biobank with linkage to
the registry information as outside the scope of REB scru-
tiny (the same REB that had indicated that registry crea-
tion was outside its scope). Of the remaining twenty-nine
sites, twenty-three viewed the biobank information as
qualitatively different from other types of personal health
information, while six indicated the difference was at
most a question of degree. One site stated that there is no
difference; all information requires sensitive handling,
whether or not it has genetic markers. Those that stated
the difference is one solely of degree generally regarded
information from the biological sample as being more
sensitive, replicable, commercializable, and predictive. Of
the sites that viewed it as qualitatively different, reasons
given were its intra-familial and inter-generational nature;
the implications for insurability and employability; the
potential uses in deciding on paternity; and its regional or
group implications, including discrimination on the basis
of race.
The twenty-nine sites were unanimous with regard to the
need for patient consent for blood samples to be placed in
the biobank. All six of the sites that had not required con-
sent for participation in the registry would now do so.
In terms of duration of consent for the biobank samples,
six stated that its duration was time-limited, eleven indi-
cated there would be no time limit for retention, five were
undecided, in three cases the answer was unclear, and in
four cases the question was skipped. Note that two of the
sites that would require periodic re-consent for the registry
alone would not require it when the biological samples
were combined with the registry. These findings demon-
strate indeterminacy on the part of REBs, as revealed by
one site's statement: "We don't have to provide answers to
all these questions. They're not all answerable."
Of the six sites who said consent would be time-limited,
one stated that "blood is different" and another that its
potential uses are endless, unlike registries. For some of
these sites, samples or linkages would be destroyed after a
set time period, ranging from five to twenty-five years.
Those indicating no time limit to consent sometimes
included one or more qualifiers, such as a withdrawal
option, and notification should there be significant
changes to the biobank. Some additional requirements
identified were: full REB review in the first year of opera-
tion; bio-collection treated as a separate protocol; periodic
report on the activities and outcomes of research using the
biobank; and scrutiny of physical security measures. As
with the diabetes registry, one site would not require peri-
odic reporting due to lack of REB resources.
Study Limitations
Interviewees had been told that the interviews would take
at maximum ninety minutes. Since questions were open-
ended, it was necessary at times that the interviewer skip
some questions in order to complete in the promised time
frame. This led to some incompleteness in results.
Note that this study was constructed around hypothetical
situations. An REB faced with a real-life application for
approval would have the opportunity to request further
details and to deliberate at length. Further, the outcomes
measure was what sites said they would do, based on these
hypothetical facts. Not all of the sites had handled all of
the types of requests included in our scenarios. Thus,
some of the answers may have reflected their understand-
ing of current guidelines, rather than reflecting past prac-
tice. In addition, responses may have been shaped in
accordance with what the interviewee expected the inter-
viewer wished to hear.
Discussion and Conclusion
We found that participants were more attuned to issues
surrounding biobanks as compared to registries, despite
similarities regarding their creation and long-term
research potential. This is not surprising given that the Tri-
Council Policy Statement (TCPS), a statement agreed to
by the major federal research funding agencies in Canada
which aims to ensure the ethical conduct of research, is
silent as to registries. Also, there is a dearth of literature,
both in Canada and internationally, concerning the role
of REBs vis-à-vis registries. There is also a significant
degree of variation in how the sites in our survey indicated
they would handle research proposals for creation and use
of these entities. For example, six of the twenty-nine sitesBMC Medical Ethics 2008, 9:17 http://www.biomedcentral.com/1472-6939/9/17
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entertaining the scenario would not require patient con-
sent for the entry of personal information into a registry,
whereas all twenty-nine would require consent for entry
of blood samples into a biobank. At least two factors are
at play in creating the consensus as to biobanking. First,
participants saw the scope of potential research activities
to be much more broad for biobanks in comparison to
registry information. Indeed, the limits for biobanks were
identified as unknowable. Second, the TCPS does contain
guidance as to human tissue, including the explicit
requirement of informed consent to its collection and use
[2].
Accompanying this greater familiarity is a dramatically
higher level of concern on the part of sites regarding
biobanks. One referred to biobank information as a 'gray
box' in that its potential future uses are at present
unknowable. Others referred to such information as pro-
viding a "total picture of the person" or "a window into
one's soul", and that "the sum is greater than the parts".
These vivid and dramatic descriptors are indicative of trep-
idation on the part of participants regarding genetic infor-
mation. There is a significant degree of ambivalence in the
literature on biobanks as to whether or not genetic infor-
mation is inherently different from other types of health
information. Some argue that all personal health informa-
tion is potentially sensitive [3]. Others lean to "genetic
exceptionalism"[4,5] despite the fact that other types of
information may also implicate family or community as
well as the individual, and may be highly sensitive (e.g.
HIV status or psychiatric record). The majority of sites in
our study (23/29) viewed genetic information as qualita-
tively different, thus weighing in on the 'exceptionalism'
side of the debate.
Given this acutely higher level of concern regarding
biobanks, it is surprising that an equal number of sites
would not require periodic renewal of consent for regis-
tries and for biobanks. Specifically, sixteen sites would
permit the entry of information into a registry to run
indefinitely or were undecided, and sixteen sites would
either permit consent to banking of a blood sample to
continue indefinitely into the future or were undecided.
One of the sites that would not require periodic renewal
of consent for the biobank in contrast to the registry pro-
vided this explanation: "No, because once the sample is
given, it's for life, you don't go a second time...up to now
it's once and for all." These findings give rise to serious
concern about consent practices regarding biobanks, espe-
cially since the samples are often retained long-term. After
describing the general standards for informed consent for
research involving human subjects in the U.S., Natalie
Ram notes that " [a]gencies and courts have been hesitant
to impose similar consent requirements on researchers
obtaining human tissue for use in research, and human
tissue research has therefore become a particularly thorny
problem for traditional formulations of informed con-
sent."[6]
One of the fascinating differences between sites with
regard to their concerns or lack thereof with identifiability
of registry data revolves around at what point in the proc-
ess they were focussing on. Sites with concerns looked at
an earlier period of time than entry into the registry – i.e.,
the fact that identifiable data were to go offsite to the prin-
cipal investigator's office prior to being de-identified. One
site indicated they would simply not allow release of per-
sonal information out-of-house, as had been proposed.
The sites that were not concerned indicated that the data
was de-identified upon entry into the registry. At least one
REB member expressed trust that researchers would safe-
guard the personal information and not attempt to re-
identify individuals.
Expansion continues apace for registries and biobanks.
This results in a need for critical analysis of suitable roles
for REBs and subsequent guidance on these topics. A first
step is to establish a dialogue on these issues, especially
regarding registries; it is hoped that this project facilitates
such discussion. Registries are of burgeoning importance
in response to demands for evidence-based decision-mak-
ing and the growth in numbers of epidemiological stud-
ies. They give rise to a number of privacy and consent
issues that outstrip current guidance and yet will need to
be dealt with by REBs.
A second step will be the provision of urgently needed
guidance regarding appropriate uses of information in
biobanks and registries. One site referred to the rapidly
changing context of genetics, and indicated that "...we're
still disoriented." Sections of the TCPS on biobanking
have not been updated since 1998 despite significant
changes in practice combined with a huge expansion in
their importance and significance. The Canadian Insti-
tutes of Health Research has developed a voluntary Best
Practices code for the handling of personal information in
health research [7]. While registries are addressed in the
document, recommendations are currently very broad;
more specific guidance as to both registries and biobanks
would be in order for future editions. Further, we call on
the Interagency Panel on Research Ethics to undertake a
review and redrafting of parts of the TCPS of direct rele-
vance to registries and biobanks. Accompanying this
should be an education programme covering these topics
aimed at researchers, REB members, and privacy commis-
sioners.
Third, we urge that REBs adopt an active role in guiding
the creation of registries and biobanks. This holistic
approach responds to the development of multi-projectBMC Medical Ethics 2008, 9:17 http://www.biomedcentral.com/1472-6939/9/17
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research platforms as opposed to simply individual
projects. Several sites were concerned about jurisdiction
and lack of specificity in being asked to review infrastruc-
ture; one site indicated that "we shouldn't be collecting
data until we know what the future use might be...this is
just a little too wide open, it's a fishing expedition." How-
ever, it is our position that since registries and biobanks
are indeed being created, it makes sense that any obvious
potential problems be addressed up-front, prior to the
infrastructure being developed. This will result in greater
efficiency and less work later for both researchers and
REBs, and the avoidance of future problems. The concern
about a 'fishing expedition' can be allayed by the fact that
the individual research projects relying on the platform
should still be subjected to REB review.
Fourth, the development of one or more specialized REBs
with expertise in the area of registries and biobanks is well
worth considering. Models that could be adapted exist in
the form of committees that specialize in screening access
to databases and in the governance of biobanks [8].
And finally, in the longer term, we suggest the develop-
ment of governing legislation. This would provide a supe-
rior form of guidance and control, given the sensitivity of
personal health information generally and of genetic
information in particular. This is particularly pertinent if
use and/or disclosure of personal health information,
including genetic material, without consent is under con-
sideration. Caulfield et al. suggest that an authorization
model for genetic databases may be superior to the
present consent regime, but that legislation would be
needed prior to adopting such a model [9,10].
The development of legislation would not be free of com-
plexities. For example, health and information are both
primarily within provincial jurisdiction. All provinces
have legislation governing information in the public sec-
tor, and most now also have legislation that covers aspects
of information-handling in the private sector. There is
also federal private sector legislation [11]. There is a lack
of consistency as to the impact of these various statutes on
the conduct of research, and often a lack of clarity. Thus,
drafters of legislation would need to take into account
these issues and contingencies. However, the difficulties
are not insurmountable, and there is an obvious sense of
need. To paraphrase one of the sites in our study:
Some of the decisions should be taken by authorities
above local REBs. Rules should be clarified so that
each local REB does not have to take decisions. Such
fundamental decisions [should] not rest upon the
shoulders of local REBs. The consequences of certain
decisions can impact on people or populations, which
makes even more [persuasive] the case for the need for
a regulatory framework on banks.
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